CTRI/2023/06/053599进行中（未招募）3 期
A phase 3, single-arm, multicenter trial to describe the safety & immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine -Naïve Adults 18 years and above of age in India.
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- Pfizer Inc.
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Generally healthy participants 18 years and above of age at the time of consent.
排除标准
- •- History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg anaphylaxis) to any component of 20vPnC, or to any other diphtheria toxoid containing vaccine.
- •- Known or suspected immune deficiency or suppression.
- •-Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk of study participation or, in the investigators judgment, make the participant inappropriate for the study.
- •-Previous vaccination with any pneumococcal vaccine, or planned receipt of any pneumococcal vaccine through study participation.
研究者
相似试验
进行中（未招募）
1 期
A Phase 3 Single-arm Study of UGN-103 for the Treatment of LG IR NMIBC.onmuscle Invasive Bladder CancerMedDRA version: 20.0Level: PTClassification code: 10005003Term: Bladder cancer Class: 100000004864CTIS2023-507261-25-00rogen Pharma Ltd.67
进行中（未招募）
1 期
An Open Study of the Efficacy and Safety of a new drug in Patients with Bladder Canceron-Muscle Invasive Bladder CancerMedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-005948-29-BGroGen Pharma Ltd.220
招募中
1 期
An Open Study of the Efficacy and Safety of a new drug in Patients with Bladder Canceron-Muscle Invasive Bladder CancerMedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-005948-29-LTroGen Pharma Ltd.220
招募中
1 期
An Open Study of the Efficacy and Safety of a new drug in Patients with Bladder CancerEUCTR2021-005948-29-ATroGen Pharma Ltd.220
已完成
不适用
A phase III, single-blind trial to assess efficacy and tolerability of genital mucosa after use of product INC056ISRCTN64791295Incrementha PD&I (Brazil)65